BMI View: The Algerian pharmaceutical market will remain attractive to multinational drugmakers,despite the slow pace of improvements in the regulatory and market access environment. Key marketdrivers such as growing demand for healthcare, rising chronic disease burden and sustained foreigninvestment in domestic drug manufacturing will continue to translate in strong market growth rates over theforecast period. Despite short-term economic and fiscal challenges, developing Algeria's pharmaceuticalindustry will remain a policy priority and therefore benefit from government incentives. This will remain inline with the broader interest by foreign drugmakers to sustain the country's ongoing plan to become aregional hub in pharmaceutical production.

Headline Expenditure Projections

- Pharmaceuticals: DZD411.62bn (USD4.12bn) in 2015 to DZD451.90bn (USD4.13bn) in 2016; +9.8%in local currency and +0.3% in US dollar terms.

Forecast in line with last quarter

- Healthcare: DZD1.11trn (USD11.14bn) in 2015 to DZD1.20trn (USD11.00bn) in 2016; +8.2% in localcurrency and -1.2% in US dollar terms. Forecast in line with last quarter.

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...